AI Is Redesigning Dental Biomaterials to Outsmart Oral Biofilms
A systematic review of 99 studies reveals how AI is transforming biomaterial design to combat drug-resistant oral infections.
Summary
Oral infections like cavities, gum disease, and implant infections are driven by stubborn bacterial biofilms that resist traditional treatments. This systematic review examined 99 studies published between 2016 and 2026 to explore how artificial intelligence is reshaping the design of dental biomaterials. By applying machine learning, deep learning, and simulation tools, AI can analyze the oral microbiome, predict how materials will perform, and optimize drug delivery to penetrate biofilms more effectively. The review identifies five core mechanisms where AI adds value — from microbiome analysis to real-time treatment adjustment — and highlights remaining challenges like poor targeting precision and difficulty translating lab findings into clinical practice. The authors propose a roadmap for next-generation AI-driven biomaterials that could make oral infection treatment far more precise and effective.
Detailed Summary
Oral infectious diseases — including dental caries, periodontitis, peri-implantitis, and endodontic infections — affect billions of people worldwide and are increasingly difficult to treat due to antimicrobial resistance driven by bacterial biofilms. Traditional biomaterials and therapies struggle to penetrate these biofilms, often induce further resistance, and fail to adapt to the constantly shifting oral environment, where pH, saliva flow, and mechanical forces change continuously. This gap between current tools and clinical need has created a compelling case for AI-driven innovation.
This systematic review, drawing on 99 articles from PubMed, Embase, and Web of Science (2016–2026), maps how artificial intelligence is being integrated into oral biomaterial research. The authors identify five core mechanisms: precise microbiome profiling, targeted material design and optimization, performance prediction via simulation, targeted drug delivery, and dynamic treatment evaluation and regulation.
Key findings show that machine learning and deep learning models can decode complex microenvironmental signals — such as pH shifts and microbial composition changes — to guide the design of responsive biomaterials that release antimicrobial agents precisely when and where needed. Multi-physics simulations allow researchers to model material behavior in realistic oral conditions before clinical testing, accelerating development timelines.
Despite these advances, significant bottlenecks remain. Current AI-driven biomaterials still lack sufficient targeting specificity, struggle with durability in the harsh oral environment, and face substantial hurdles in clinical translation due to regulatory complexity and limited real-world validation.
The authors propose a forward-looking agenda: multimodal material design for better targeting, structural optimization for durability, multi-mechanism biofilm disruption strategies, and deeper AI integration across the full biomaterial development pipeline. For clinicians and researchers, this review signals that precision oral medicine — where treatments adapt in real time to individual microbiome profiles — is no longer theoretical but an emerging clinical reality requiring coordinated translational effort.
Key Findings
- AI-optimized biomaterials can decode oral microenvironmental signals like pH shifts to trigger targeted antimicrobial release.
- Machine learning accelerates biomaterial design by predicting performance before costly lab or clinical testing.
- Current AI-driven materials still lack sufficient biofilm penetration and targeting precision for reliable clinical use.
- Multi-physics simulation enables realistic modeling of material behavior under saliva flow and chewing forces.
- Clinical translation remains the biggest bottleneck, requiring stronger regulatory pathways and real-world validation studies.
Methodology
This is a systematic review of 99 articles retrieved from PubMed, Embase, and Web of Science covering January 2016 to January 2026. Search terms spanned three dimensions: AI, biomaterials, and oral microbiome, with defined inclusion and exclusion criteria applied to select final studies.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so detailed methodology, individual study quality assessments, and specific quantitative findings cannot be evaluated. As a systematic review, findings reflect the quality and heterogeneity of the underlying studies, which may vary considerably. Clinical translation of AI-driven biomaterials remains largely preclinical, limiting immediate applicability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.